SCHEMBL6690463

SCHEMBL6690463

Cc1ccc(S(=O)(=O)OC[C@@H]2CN(C(=O)OCc3ccccc3)CC[C@@H]2c2ccc(F)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.42
RORC P51449 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GRIN2B Q13224 4/20 0.42
F13A1 P00488 2/20 0.41
TGM2 P21980 2/20 0.41
TGM1 P22735 2/20 0.41
PDE4B Q07343 1/20 0.41
CYP2C19 P33261 1/20 0.41
MMP1 P03956 2/20 0.41
MMP3 P08254 2/20 0.41
MMP7 P09237 2/20 0.41
MMP9 P14780 2/20 0.41
MMP13 P45452 1/20 0.41
TRPC3 Q13507 1/20 0.40
TRPC7 Q9HCX4 1/20 0.40
MMP2 P08253 1/20 0.40
MMP8 P22894 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689652 1.00 P2RX7 (0.42) P2RX7RORCSMN1; SMN2NPC1RAB9A
SCHEMBL6690460 1.00 P2RX7 (0.42) P2RX7RORCSMN1; SMN2NPC1RAB9A
SCHEMBL6693784 0.94 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL6694471 0.94 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL6694472 0.94 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL6692600 0.89 SMN1; SMN2 (0.40) P2RX7RORCSMN1; SMN2NPC1RAB9A
SCHEMBL6690204 0.88 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL6690206 0.88 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL6851928 0.88 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL7212149 0.88 SMN1; SMN2 (0.46) RORCSMN1; SMN2NPC1RAB9AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0812827-A1 Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1997-12-17 EP claimed
US-6815548-B2 MINTERMEDIATE FOR PHARMACEUTICALS SUCH AS PAROXETINE USEFUL AS ANTIDEPRESSANTS, REPRESENTED BY THE GENERAL FORMULA (I): SUMIKA FINE CHEMICALS CO., LTD. (JP) 2004-11-09 US disclosed
EP-1394160-A1 Process for preparing crystalline paroxetin hydrochloride SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-03-03 EP disclosed
EP-1384720-A1 Process for drying paroxetine hydrochloride SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-01-28 EP disclosed
EP-1384711-A1 Optical resolution of a piperidine derivative SUMIKA FINE CHEMICALS Co., Ltd. (JP) 2004-01-28 EP disclosed
US-6610851-B1 1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-((3,4-methylene dioxyphenyl)oxymethyl)piperidine; reacting 4-(4-fluorophenyl)-3-hydroxymethylpiperidine with di-tert-butyl dicarbonate to form the carbamate; 3,4-methylenedioxyphenol SUMIKA FINE CHEMICALS CO., LTD. (JP) 2003-08-26 US disclosed
US-20030144519-A1 Process for preparing a piperidine derivative SUMIKA FINE CHEMICALS CO., LTD. 2003-07-31 US disclosed
US-6476227-B1 Piperidine derivative and process for preparing the same SUMIKA FINE CHEMICALS CO., LTD. (JP) 2002-11-05 US disclosed
US-5948914-A PREPARING 4-(4-FLUOROPHENYL)-3-HYDROXYMETHYLPIPERIDINE BY OPTICALLY RESOLVING WITH O-CHLOROTARTRANILIC ACID; CHEMICAL INTERMEDIATE FOR DRUGS SUMIKA FINE CHEMICALS CO., LTD. (JP) 1999-09-07 US disclosed
EP-0812827-A1 Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation SUMIKA FINE CHEMICALS Co., Ltd. (JP) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144519-A1 Process for preparing a piperidine derivative TPH1, TPH2, HTR7 P2RX7 1564/4885RORC 1570/4885SMN1; SMN2 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.